A hidden genetic marker in Southeast Asia could trigger severe drug reactions
In short: For many patients in Southeast Asia, a routine prescription for epilepsy could trigger a life-threatening immune response. The culprit is a specific genetic variant, the HLA-B*15:02 allele, which is significantly more prevalent in Asian populations than in other regions of the world.
Carrying the HLA-B*15:02 allele significantly increases the likelihood of experiencing severe cutaneous adverse drug reactions (SCARs). These reactions occur when certain antiepileptic medications trigger an intense immune response in the skin. Research indicates that the prevalence of this allele varies significantly across different Asian populations, creating a critical need for personalized medical screening. This genetic variation is particularly notable because its presence can lead to dangerous skin conditions. Understanding these risks is essential for improving patient safety during treatment.
In Southeast Asia, the prevalence of HLA-B*15:02 is estimated at 5.6% ± 3.1%. Such figures are higher than those recorded in West Asia (0.01% ± 0.05%), North-East Asia (0.6% ± 0.9%), or South Asia (2.1% ± 1.5%). When looking at specific countries, the Philippines shows the highest prevalence at 22%, followed by Vietnam at 13.5%, Indonesia at 11.9%, and Malaysia at 10%. Singapore sits at 8.1% ± 3.7%. The distribution of this allele is statistically significant across these diverse groups. This variation highlights the importance of regional genomic data in clinical settings.
Clinical guidelines from international pharmacogenomics working groups have identified four specific drugs with strong evidence (Level 1 A) for causing SCARs in carriers of this allele: carbamazepine, oxcarbazepine, lamotrigine, and phenytoin. While most evidence for lamotrigine-related reactions comes from the Han Chinese population, international experts now recommend or require preemptive genotyping for at least three of these drugs—carbamazepine, oxcarbazepine, and phenytoin—to mitigate risks in high-prevalence regions. Implementing preemptive testing could substantially lower the incidence of these adverse reactions in the region. Such proactive measures represent a vital frontier in precision medicine.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Investigation of the Prevalence of the <i>HLA-B*15:02</i> Allele in the Asian Populations: A Comprehensive Analysis Through Using AFND.
- Also: North–South Line (Singapore)
To cite this card, link to https://intellectplus.co.uk/app/health-north-south-line-singapore.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Future Frontier · More in Health · Latest · A–Z · All topics
